9 Meters Biopharma (NMTR) Receives Orphan Drug Designation for NM-003, Proprietary Long-Acting GLP-2, for Prevention of aGvHD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/26/2026

1. ON
2. SYNA
3. SPY
4. MU
5. AAPL
6. VEON
7. DRI
8. NVDA
9. FDXF
10. RKLB

Go back to 9 Meters Biopharma (NMTR) Receives Orphan Drug Designation for NM-003, Proprietary Long-Acting GLP-2, for Prevention of aGvHD

9 Meters Biopharma, Inc. Receives Orphan Drug Designation for NM-003, a Proprietary Long-Acting GLP-2, for Prevention of Acute Graft Versus Host Disease (aGvHD)

December 9, 2020 7:37 AM EST

aGvHD among potential indications being considered for next stage of development

Candidate to move to IND-enabling studies in 2021

RALEIGH, NC / ACCESSWIRE / December 9, 2020 / 9 Meters Biopharma, Inc. (NASDAQ: NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to NM-003, a proprietary long-acting GLP-2 receptor agonist, for prevention of acute graft versus host disease.

NM-003, also called teduglutide, is designed as a long-acting injectable glucagon-like-peptide-2 (GLP-2) receptor agonist that utilizes proprietary XTEN... More